Table 2.
Virological data, serum and saliva antibody status of study participants.
| Variables | HC (n = 57) | P-value | PLHIV (n = 58) | P-value | ||
|---|---|---|---|---|---|---|
| High responder(n = 28) | Low responder(n = 29) | High responder(n = 20) | Low responder(n = 38) | |||
| Virological data | ||||||
| PCR-positive at baseline | 1 | 1 | ||||
| Yes B | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| No B | 28 (100) | 29 (100) | 20 (100) | 38 (100) | ||
| Antibody-positive at baseline | 1 | 1 | ||||
| Yes B | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| No B | 28 (100) | 29 (100) | 20 (100) | 38 (100) | ||
| CD4 count | NA | NA | NA | 0.765 | ||
| ≤ 300 B (cells/mm3) | NA | NA | 6 (30) | 10 (26.3) | ||
| > 300 B (cells/mm3) | NA | NA | 14 (70) | 28 (73.7) | ||
| Serum antibody level (AU) | ||||||
| Anti-S d0 A | 0.4 (0) | 0.4 (0) | 1 | 0.4 (0) | 0.4 (0) | 1 |
| Anti-S d10 A | 0.8 (1.4) | 0.4 (0.9) | 0.090 | 0.4 (1.6) | 0.9 (1.7) | 0.395 |
| Anti-S d21 A | 57.4 (119.9) | 62.4 (149) | 0.786 | 43.4 (81.6) | 19.6 (39.7) | 0.015* |
| Anti-S d35 A | 2368.5 (1189) | 1625 (2878.5) | 0.231 | 1972 (1526) | 1049 (1338) | 0.005* |
| Anti-S mo.6 A | 739.5 (691.3) | 559 (737.5) | 0.078 | 782 (967) | 249 (412.5) | <0.001* |
| Positive seroconversion | 0.999 | 1 | ||||
| d.35 Yes B | 28 (100) | 29 (100) | 20 (100) | 38 (100) | ||
| mo 6.Yes B | 28 (100) | 28 (96.6) | 20 (100) | 38(100) | ||
| Saliva antibody level (MFI) | ||||||
|
Anti-S-f d.0
Over cutoff (55 MFI) B |
0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| Anti-S-f d.10 A (MFI) | 78 (306) | 30 (32) | 0.003* | 78.5 (34.8) | 41 (65.3) | 0.098 |
| Anti-S-f d.21 A (MFI) | 540 (654) | 203 (415) | 0.028* | 340 (438.8) | 159 (315.5) | 0.012* |
| Anti-S-f d.35 A (MFI) | 3248 (3287) | 571 (1994.5) | <0.001* | 3875 (6557) | 1251 (2166.5) | 0.001* |
| Anti-S-f mo.6 A (MFI) | 438.00 (402.50) | 68. (86.5) | <0.001* | 567 (362.5) | 116.5 (120) | <0.001* |
|
Anti-S1 d.0
Over cutoff (98 MFI) B |
0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| Anti-S1 d.10 A (MFI) | 52 (34) | 32 (18) | 0.003* | 53 (66) | 38 (49.3) | 0.105 |
| Anti-S1 d.21 A (MFI) | 332 (426) | 161 (273) | 0.076 | 244.5 (308) | 107 (163.5) | 0.020* |
| Anti-S1 d.35 A (MFI) | 2512 (2141) | 400 (1618) | 0.001* | 2362 (4715.8) | 941 (1859.5) | 0.004* |
| Anti-S1 mo.6 A (MFI) | 273 (216) | 56 (59.5) | <0.001* | 321.5 (200) | 85 (61.3) | <0.001* |
| Fold change relative to baseline | ||||||
| Anti-S-f d.10-fold change A | 2.3 (10.6) | 1.1 (0.9) | 0.010* | 2.3 (4.6) | 1.3 (2.2) | 0.351 |
| Anti-S-f d.21-fold change A | 18 (22.5) | 7.8 (13.4) | 0.028* | 12.4 (13.7) | 5.4 (11.4) | 0.033* |
| Anti-S-f d.35-fold change A | 102 (116.8) | 23.8 (67.3) | 0.002* | 133.5 (274.8) | 37.2 (66.5) | 0.002* |
| Anti-S-f mo.6-fold change A | 15.2 (15.4) | 2.5 (3) | <0.001* | 18 (15.4) | 4.2 (4) | <0.001* |
Mann–Whitney U test was applied to compare the continuous variables and X2 test for analyzing categorical variables using SPSS version 24.0 (IBM Crop, Armonk, NY, USA) software. A variable is illustrated as the median (IQR), whereas B variable is illustrated as the number (%). * Bolded values denotes statistical significance when P-value is < 0.05. NA, not applicable; IQR, interquartile range; d, day; mo, months; S1, spike antigen; S-f, full-length trimeric spike; MFI, mass fluorescence intensity.